Galapagos and Gilead Sciences Post Successful Yet Disappointing Filgotinib Results
Gilead Sciences (NASDAQ: GILD) and its collaboration partner, Galapagos (NASDAQ: GLPG), reported somewhat disappointing news for their anti-inflammatory candidate, filgotinib. The potential blockbuster helped patients with ulcerative colitis achieve remission, but perhaps not as well as Rinvoq, a similar drug from AbbVie (NYSE: ABBV) currently approved to treat patients with rheumatoid arthritis.
Ulcerative colitis patients who hadn't previously been treated with an injectable drug were significantly more likely to achieve remission with filgotinib than those given a placebo, but it looks like Gilead Sciences and Galapagos could have trouble competing with AbbVie for this population.
Image source: Getty Images.
Source Fool.com
